Results 11 to 20 of about 43,705 (217)
Molecular Mechanisms of Gemcitabine Resistance in Cholangiocarcinoma. [PDF]
Oncol ResCholangiocarcinoma (CCA) is an aggressive cancer originating from bile duct epithelium. Surgical resection remains the primary curative treatment for CCA. However, most CCA patients are diagnosed at an advanced stage, which limits the applicability of surgical resection. Gemcitabine is widely used as a first-line chemotherapeutic agent for unresectable
Kidoikhammouan S +3 more
europepmc +3 more sources
Cell Death and Disease, 2021 The poor prognosis of pancreatic cancer is primarily due to the development of resistance to therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been shown to interact with enhancer of zeste 2 polycomb repressive complex 2 ...
Yan Sun +5 more
doaj +1 more source
Biomedicines, 2022 Treatment of pancreatic ductal adenocarcinoma (PDAC), a dismal disease with poor survival rates, is hampered by the high prevalence of chemotherapy resistance.
C. Arnold Spek +2 more
doaj +1 more source
WRQ-2, a gemcitabine prodrug, reverses gemcitabine resistance caused by hENT1 inhibition
Drug Discoveries & Therapeutics, 2022 Gemcitabine is widely used in the clinic as a first-line antitumor agent. However, intrinsic and acquired resistance hinders its wide clinical application. In this study, a gemcitabine prodrug nominated as WRQ-2 was designed and synthesized by conjugating gemcitabine with the indole-3-methanol analogue OSU-A9 through a carbamate linkage.
Wang, Ruquan +3 more
openaire +2 more sources
Diagnostic Microdosing Approach to Study Gemcitabine Resistance [PDF]
Chemical Research in Toxicology, 2016 Gemcitabine metabolites cause the termination of DNA replication and induction of apoptosis. We determined whether subtherapeutic "microdoses" of gemcitabine are incorporated into DNA at levels that correlate to drug cytotoxicity. A pair of nearly isogenic bladder cancer cell lines differing in resistance to several chemotherapy drugs were treated with
Scharadin, Tiffany M +9 more
openaire +4 more sources
GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer [PDF]
PeerJ, 2022 Background Pancreatic ductal adenocarcinoma (PDAC) has the worst five-year overall survival rate among all cancer types. Acquired chemoresistance is considered one of the main reasons for this dismal prognosis, and the mechanism of chemoresistance is ...
Chen Chen +5 more
doaj +2 more sources
Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway. [PDF]
PLoS ONE, 2016 Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs.
Zhen-Hua Wu +5 more
doaj +1 more source
Gemcitabine in Bone Sarcoma Resistant to Doxorubicin‐BasedChemotherapy [PDF]
Sarcoma, 2000 Subjects and Methods: Seven patients with progressive localized or metastatic chemo‐resistant osteosarcoma were treated by gemcitabine.The protocol included gemcitabine 1000 mg/m2/w for 7 consecutive weeks, followed by 1 week rest.
Merimsky, Ofer +5 more
openaire +2 more sources
Cell Death and Disease, 2021 Gemcitabine is the first-line chemotherapy drug for cholangiocarcinoma (CCA), but acquired resistance has been frequently observed in CCA patients. To search for potential long noncoding RNAs (lncRNAs) involved in gemcitabine resistance, two gemcitabine ...
Min Lu +6 more
doaj +1 more source
Experimental and Molecular Medicine, 2020 Pancreatic cancer: Exploring a pathway to drug resistance A cell membrane protein called PROM2 promotes the resistance of pancreatic cancer to the anti-cancer drug gemcitabine, suggesting PROM2 and the molecular signaling pathway it stimulates could be ...
Wenbin Li +7 more
doaj +1 more source